XTL Biopharmaceuticals Ltd.

121 articles about XTL Biopharmaceuticals Ltd.

• XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

  10/20/2023

  XTL Biopharmaceuticals Ltd. announced that the Company received a written notification from the Nasdaq Stock Market LLC on October 18, 2023, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Rules for continued listing on the Nasdaq.

• XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update

  7/24/2018

  The Company is expanding its IP portfolio surrounding hCDR1 and has decided to reduce its research and development expenditures in connection with execution of its clinical trials.

• XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update

  5/29/2018

  XTL Biopharmaceuticals Ltd. announced financial results for the quarter ended March 31, 2018.

• XTL Biopharma Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements

  12/7/2017

  XTL Biopharma today announced that it has received notification from the NASDAQ that the Company has regained compliance with the minimum $2.5M stockholders' equity requirement for continued listing on The Nasdaq Capital Market.

• XTL Biopharma Reports Third Quarter 2017 Financial Results

  11/27/2017

  XTL reported approximately $6,085 thousand in cash and cash equivalents as of September 30, 2017, an increase of $4,066 thousand since December 31, 2016.

• XTL Receives Notification From NASDAQ Regarding Continuing Listing Requirements

  10/23/2017

  XTL today announced that on October 17, 2017, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company has failed to comply with the continued listing requirement that it maintain either a minimum of $2,500,000 in stockholders' equity or $35,000,000 market value of listed securities or $500,000 of net income.

• XTL Biopharma Reports First Half 2017 Financial Results & Provides Clinical And Operational Update

  9/26/2017

• XTL Biopharma Unveils Additional Expanded hCDR1 Preclinical Data For The Treatment Of Sjogren's Syndrome

  9/12/2017

• XTL Biopharma Reports First Quarter 2017 Financial Results & Provides Clinical And Operational Update

  6/15/2017

• XTL Biopharma Appoints Mr. Alex Rabinovich To Its Board Of Directors

  4/27/2017

• XTL Biopharma Unveils Expanded hCDR1 Preclinical Data For The Treatment Of Sjögren’s Syndrome

  4/5/2017

• XTL Biopharma Reports 2016 Financial Results & Provides Clinical And Operational Update

  3/30/2017

• XTL Biopharma Announces Closing of $2.8 Million Private Placement From Existing Investors

  3/22/2017

• XTL Biopharma Announces $2.8 Million Private Placement From Existing Investors

  3/8/2017

• XTL Biopharma Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement

  3/1/2017

• XTL Biopharma Announces $2.5 Million Registered Direct Offering

  2/17/2017

• XTL Biopharma Expands Clinical Advisory Board To Support Phase II Study Of HCDR1 In Sjogren's Syndrome

  2/13/2017

• XTL Biopharma Announces Ratio Change Of Its Depositary Receipt Program

  1/27/2017

• XTL Biopharma' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome

  1/5/2017

• XTL Biopharma Reports Third Quarter 2016 Financial Results & Provides Clinical And Operational Update

  12/6/2016